On Friday, Poseida Therapeutics Inc (NASDAQ: PSTX) was -3.54% drop from the session before settling in for the closing price of $2.54. A 52-week range for PSTX has been $1.83 – $4.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 53.46% over the past five years. When this article was written, the company’s average yearly earnings per share was at -3.10%. With a float of $65.08 million, this company’s outstanding shares have now reached $95.64 million.
Let’s look at the performance matrix of the company that is accounted for 330 employees. In terms of profitability, gross margin is 90.56%, operating margin of -133.92%, and the pretax margin is -127.36%.
Poseida Therapeutics Inc (PSTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Poseida Therapeutics Inc stocks. The insider ownership of Poseida Therapeutics Inc is 33.00%, while institutional ownership is 50.07%.
Poseida Therapeutics Inc (PSTX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.35 earnings per share (EPS) during the time that was less than consensus figure (set at -0.29) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.70% during the next five years compared to -12.83% drop over the previous five years of trading.
Poseida Therapeutics Inc (NASDAQ: PSTX) Trading Performance Indicators
You can see what Poseida Therapeutics Inc (PSTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.69. Likewise, its price to free cash flow for the trailing twelve months is 1133.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of Poseida Therapeutics Inc (PSTX)
Poseida Therapeutics Inc (NASDAQ: PSTX) saw its 5-day average volume 0.51 million, a negative change from its year-to-date volume of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 35.71%. Additionally, its Average True Range was 0.16.
During the past 100 days, Poseida Therapeutics Inc’s (PSTX) raw stochastic average was set at 2.32%, which indicates a significant decrease from 8.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.23% in the past 14 days, which was lower than the 74.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.84, while its 200-day Moving Average is $3.02. Nevertheless, the first resistance level for the watch stands at $2.53 in the near term. At $2.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.66. If the price goes on to break the first support level at $2.40, it is likely to go to the next support level at $2.36. The third support level lies at $2.27 if the price breaches the second support level.
Poseida Therapeutics Inc (NASDAQ: PSTX) Key Stats
There are 96,958K outstanding shares of the company, which has a market capitalization of 237.97 million. As of now, sales total 64,700 K while income totals -123,430 K. Its latest quarter income was 25,970 K while its last quarter net income were -31,370 K.
